Cargando…
Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022
[Image: see text] The accelerated appearance of drug-resistant bacteria poses an ever-growing threat to modern medicine’s capacity to fight infectious diseases. Gram-positive species such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae continue to contribute signif...
Autores principales: | van Groesen, Emma, Innocenti, Paolo, Martin, Nathaniel I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379927/ https://www.ncbi.nlm.nih.gov/pubmed/35895325 http://dx.doi.org/10.1021/acsinfecdis.2c00253 |
Ejemplares similares
-
Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics
por: Olsuf’eva, E. N., et al.
Publicado: (2006) -
Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
por: Balzarini, Jan, et al.
Publicado: (2006) -
Synthetic Biology
Facilitates Semisynthetic Development
of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant Enterococcus
por: Koteva, Kalinka, et al.
Publicado: (2023) -
Eremomycin pyrrolidide: a novel semisynthetic glycopeptide with improved chemotherapeutic properties
por: Olsufyeva, Evgenia N, et al.
Publicado: (2018) -
Developments in Glycopeptide Antibiotics
por: Blaskovich, Mark A. T., et al.
Publicado: (2018)